CytomX Therapeutics, Inc. (CTMX) · Aug 6, 2026 · Company update

Revenue missed sharply, while pipeline progress and cash runway held steady

Revenue missed sharply, while pipeline progress and cash runway held steady

The quarter missed the limited published financial bar. Q2 revenue was $1.4 million versus a published consensus of roughly $12.6 million, while EPS was $(0.09) versus an expected $(0.08), making the headline result worse than anticipated. The revenue gap is largely timing-related: prior Bristol Myers Squibb obligations were completed in 2025 and the Astellas collaboration wound down during Q2, rather than reflecting a new commercial deterioration.

MetricQ2 2026Comparison / expectation
Revenue$1.4 million$18.7 million in Q2 2025; published consensus ~$12.6 million (Income Statement; published consensus)
EPS$(0.09)$(0.00) in Q2 2025; published consensus $(0.08) (Income Statement; published consensus)
R&D expense$17.6 million$13.3 million in Q2 2025 (Income Statement)
Total operating expense$25.2 million$19.9 million in Q2 2025 (Income Statement)
Cash, cash equivalents and investments$330.3 million$346.7 million at March 31, 2026 (Financial Highlights)

The clinical update is progress, not a de-risking event. Varseta-M enrollment is complete at 113 patients, new expansion cohorts are starting in three additional gastrointestinal cancers, and the company still targets a late-2026 data update and a first registrational study in the first half of 2027. But the filing provides no efficacy data, no dose-selection result, and no change to those previously expected milestones; the near-term investment case remains dependent on future clinical readouts (Pipeline Program Updates — Varseta-M).

The balance sheet is the main offset to the earnings miss. CytomX reported a projected cash runway through at least the second half of 2028, and the $37.0 million Regeneron target-selection payment received in July is not included in the June 30 cash figure. That payment and the broader Regeneron expansion were already announced before this filing, so they improve funding visibility more than they add fresh surprise today (Corporate and Financial; Condensed Balance Sheets).

Net: modestly worse than expected financially, with no new clinical catalyst to reverse the read. Higher R&D spending reflects manufacturing and development activity for Varseta-M, while the collaboration-driven revenue decline is explainable; nevertheless, the actual quarter missed consensus and the filing mainly reaffirmed an already-known pipeline and partnership setup rather than delivering new evidence of clinical success.

Original filing on SEC EDGAR

Revenue missed sharply, while pipeline progress and cash runway held steady | CTMX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.